Ph II Cabazitaxel DD Liposarcoma

Inclusion Criteria: * Local diagnosis of dedifferentiated liposarcoma * Age 18-75 yrs * WHO performance status 0-1 * Radiological or histological diagnosis of inoperable locally advanced or metastatic disease, with evidence of disease progression within the past 6 months * Clinically and/or radiographically documented measurable disease within 21 days prior to randomization.At least one site of disease must be unidimensionally measurable according to RECIST 1.1. * One previous chemotherapy regimen for locally advanced or metastatic dedifferentiated liposarcoma (this could include pre-operative chemotherapy for primary disease if subsequent complete resection was not achieved). * Adequate haematological, renal and hepatic function * Birth control measures * Estimated life expectancy \> 3 months * Related adverse events from previous therapies ≤ Grade 1 * Written informed consent Exclusion Criteria: * More than 1 prior molecularly targeted therapy (e.g. CDK4 inhibitor). Any prior such therapy must be completed at least 4 weeks before randomization. * Symptomatic CNS metastases * Previous encephalopathy of any cause or other significant neurological condition * Concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450 3A4/5 * Pregnancy * inflammation of the urinary bladder (cystitis) * Other invasive malignancy within 5 years (exceptions of non-melanoma skin cancer, localized cervical cancer, localized and presumably cured prostate cancer or adequately treated basal or squamous cell skin carcinoma) * Significant cardiac disease * Uncontrolled severe illness or medical condition, other than DD liposarcoma * Hypersensitivity to taxanes or their excipients